Guidance on Good Practice in Cost-Effectiveness Modeling: Is More Needed?

Kassirer JP , Angell M. The journal's policy on cost effectiveness analyses [editorial]. N Engl J Med. 1994;331(10):669—70.

Sheldon TA Problems of using modelling in the economic evaluation of health care. Health Econ. 1996;5(1):1—11.

Drummond MF Economic analysis alongside clinical trials: problems and potential. J Rheumatol. 1995;22:1403—7.

Drummond M. Cost effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Econ. 1992;1:85—92.

Drummond M. , Sculpher MJ , Torrance GW , O'Brien BJ , Stoddart GL Economic Evaluation of Health Care Programmes. 3rd ed. Oxford (UK): Oxford University Press; 2005.

Gold MR , Siegel JE , Russell LB , Weinstein MC Cost Effectiveness in Health and Medicine. Oxford (UK): Oxford University Press; 1996.

Akehurst R. , Anderson P. , Brazier J. , et al. Decision analytic modeling in the economic evaluation of health technologies. Pharmacoeconomics. 2000;17:443—4.

Weinstein MC , O'Brien B. , Hornberger J. , et al. Principles of good practice for decision analytic modelling in health care evaluation: report of the ISPOR Task Force on Good Research Practices—modelling studies. Value Health. 2003;6(1):9—17.

Nice. Guide to the Methods of Health Technology Appraisal. London: NICE; 2004.

Department of Health and Aging, Australian Government. Pharmaceutical benefits—committees. Available from: URL: http://www.health.gov.au/internet/wcms/publishing.nsf/content/healthpbs-general-committ.htm .

Canadian Agency for Drugs and Technologies in Health. Available from: URL: http://www.cadth.ca/index.php/en/home .

Haute Autorite de Sante. Available from: URL: http://www.has-sante.fr/portail/display.jsp?id=j_5.

Institute for Quality and Efficiency in Health Care. Available from: URL: http://www.iqwig.de/ .

Norwegian Medicines Agency. Available from: URL: http://www.legemiddelverket.no/templates/InterPage____15421.aspx . 15. Karnon J. , Brennan A. , Akehurst RL A critique and impact analysis of decision modeling assumptions. Med Decis Making. 2007 ;27:491—499.

Miners AH , Garau M. , Fidan D. , Fischer A. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study . BMJ. 2005;330:65—8.

Chilcott J. , McCabe C. , Tappenden P. , et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis . BMJ. 2003;326:526—31.

Drummond MF , Jefferson TO Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996 ;313:2075—83.